Skip to Main Navigation

Purchasing pharmaceuticals (English)

The overall aim of this paper is to contribute to the understanding of Resource Allocation and Purchasing (RAP) arrangements as regards pharmaceuticals in developing countries. The specific objective of this paper is to examine the strategic questions that arise, when pursuing an active purchasing and resource allocation strategy for drugs, as well as the actual practice and experience from applying different RAP strategies to promote access of the poor to essential drugs, i.e. availability of affordable essential drugs of good quality and appropriate and efficient use of drugs.

Details

  • Author

    Enemark, Ulrika Alban, Anita Vazquez, Enrique C.S.

  • Document Date

    2004/09/01

  • Document Type

    Working Paper

  • Report Number

    31500

  • Volume No

    1

  • Total Volume(s)

    1

  • Country

    World,

  • Region

    The World Region,

  • Disclosure Date

    2010/07/01

  • Doc Name

    Purchasing pharmaceuticals

  • Keywords

    Rational Selection and Use of Medicines;number of people with access;Rational Use of Drugs;financing of health care;social health insurance schemes;providers of health services;revenue from user charges;quality of health services;share of health expenditure;national health insurance scheme;essential drugs list;access to drugs;availability of drug;consumption of drugs;private sector provider;civil service rules;social insurance scheme;standard treatment guidelines;social security financing;preventive health services;cost of illness;level of delivery;treatment of diseases;effect on health;collection of information;health care financing;tax collection system;number of beneficiaries;health care professional;human resource planning;community drug schemes;allocation of resource;local health center;brand name drugs;scale production;quality control mechanism;reimbursement of expenditures;informal sector worker;public sector performance;scale of production;health care system;formal sector employment;rational drug use;health service scheme;flow of fund;risk of transmission;weak financial management;cost effectiveness analysis;source of funding;central government agency;resource allocation function;administration to patients;public sector accountability;health sector spending;society must;access to pharmaceuticals;spot market transaction;level of private;cost of drug;lack of competition;cost of pharmaceuticals;distribution of pharmaceuticals;intellectual property rights;quality of care;interests of consumer;regulation of drug;health care expenditure;share of revenue;social insurance coverage;pool of fund;financing health services;lack of knowledge;health facility;drug therapy;strategic issue;generic drug;supply side;remote area;community financing;pharmaceutical expenditure;drug financing;irrational use;population group;private finance;information asymmetry;drug resistance;public health;competitive environment;payment system;drug supply;revolving fund;drug list;adverse incentive;deprived regions;pharmaceutical policy;pharmaceutical sector;private insurance;free drug;chronic condition;Financial Access;financial implication;retail market;socio-economic status;moral hazard;private expenditure;affordable price;increased access;financial barrier;geographical area;private market;resource constraint;essential medicines;vulnerable group;market characteristic;traditional healer;chronic disease;fee system;exemption policy;exemption system;public system;reducing prices;financial incentive;scarce resource;income quintile;catering services;disease challenge;child welfare;target beneficiary;physical infrastructure;perverse incentives;educational activities;generic substitution;rural area;outpatient department;drug sellers;compulsory membership;local situation;production level;pool financing;drug delivery;individual transaction;limited resources;social medicine;treatment course;payment mechanism;private clinic;incentive regime;medical doctor;medical treatment;foreign exchange;government health;medical advice;lost revenue;affordable drug;fee revenue;insufficient fund;financial disbursement;medical equipment;hard copy;insurance plan;patient compliance;reinsurance arrangement;private spending;systems development;diagnostic facility;negative effect;pharmaceutical spending;household expenditure;specialized care;comparative study;drug policy;cost sharing;financial loss;private provider;multinational level;drug production;health finance;macroeconomic constraints;policy option;health status;social accountability;purchase transaction;asian countries;patent drugs;government cash;access cost;global market;production process;drug store;private pharmacies;budget constraint;sustainable financing;profit sector;central guideline;payment modality;financial protection;referral service;contract services;price reduction;storage system;national system;future research;risk sharing;curative care;geographical distribution;drug budget;Public Spending;short supply

Downloads

COMPLETE REPORT

Official version of document (may contain signatures, etc)

  • TXT*
  • Total Downloads** :
  • Download Stats
  • *The text version is uncorrected OCR text and is included solely to benefit users with slow connectivity.

Citation

Enemark, Ulrika Alban, Anita Vazquez, Enrique C.S.

Purchasing pharmaceuticals (English). Health, Nutrition and Population (HNP) discussion paper Washington, D.C. : World Bank Group. http://documents.worldbank.org/curated/en/918691468762351126/Purchasing-pharmaceuticals